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Abstract 
The article is concerned with biomedical technologies and the entrepreneurial ways through 
which these vital technologies come to life. Focusing on stem cell ‘clinical trials’ conducted in 
hospitals in Việt Nam, it traces the processes through which tentative experiments and 
uncertain results are being translated into commercial ventures. It pays particular attention 
to the complex institutional settings and collaborative engagements through which 
biomedical enterprise and markets come to be instituted. Of particular concern are network 
partnerships involving public bodies, policy makers and private business interests that 
facilitate the process of turning clinical experiments into vetted therapies for the healthcare 
marketplace. The article contributes to anthropological reflections on emerging bioscience 
economic formations that are widely termed as ‘bioeconomies’. It does so, by reorienting the 
analytical gaze away from understandings of economic value as inherently rooted in biological 
substances that hold a future promise of cure, towards ongoing processes of assembling 
biomedical entrepreneurial networks and turning biotechnical matters into commodities. 
 




In recent decades, there has been a growing interest in, and expectations for, the 
development of a global biotechnology industry. Stem cell science, which offers the prospect 
for developing treatments for severe and often fatal conditions by harnessing the 
regenerative powers of the cell, has been seized upon by governments and business interests 
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around the world as a particularly promising area of investment. The economic potential of 
stem cell technologies has been of intense interest not only to policy makers and venture 
capitalists but also to social scientists. Anthropologists and science studies scholars have 
become concerned with the increasing entanglement of contemporary life sciences and 
economic processes, a relation often summarised under the term ‘bioeconomy’ (Birch and 
Tyfield, 2012; Cooper, 2008a; Petersen and Krisjansen, 2015; Rajan, 2006; Rose, 2007; Waldby 
and Mitchell, 2006). Despite a wealth of reflections on ‘bioeconomy’ there is still little known 
about the actual ways in which biomedical innovation is produced and translated into 
commercial applications, and how science-based industries and markets come to life. The 
current article addresses such gaps in our knowledge by studying in ethnographic ways the 
scientific and social practices through which stem cell commercial applications and ventures 
take shape. Focusing on stem cell ‘clinical trials’ conducted in Vietnamese hospitals, the article 
considers the process through which tentative experiments and uncertain results are being 
turned into commodities for the healthcare marketplace, highlighting the complex 
institutional settings and collaborative engagements involved in this transformative process. 
Experiments conducted in public hospitals in the capital Hà Nội under the auspices of health 
departments and sponsorship by biotech firms provide ample scope for detailing such 
complex collaborative flows. 
This first ethnographic account on stem cell practices in Việt Nam provides an 
interesting case through which to consider the rise of a global biotechnology industry and its 
local variations, a global-local relation theme that has been recurrent in anthropological 
discussions of contemporary biotechnology (Ong & Collier 2005; Sleeboom-Faulkner 2014). 
The emergence of bioscience economic formations in Asian settings has been a key area of 
focus for such discussions (Ong & Chen 2010; Rajan 2010; Sleeboom-Faulkner 2011). The rise 
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of competitive bioindustries in Asia and their often hazardous laissez-faire approach to stem 
cell experimentation and science regulation have been key points of concern for many 
studies. China, India and Singapore in particular have served as cases for considering the 
challenges life science practices, and their perilous coupling with fiercely competitive 
economics and potent Asian nationalisms, pose to science ethics, citizenship and democratic 
governance (Ong 2006; Ong & Chen 2010; Salter 2008; Song 2011).  In China and Singapore, 
Ong observes (2006), respective governments have sought to build competitive bioindustries 
by carving out zones of exception that operate outside national science and market 
regulations, hence engineering areas for scientific and political experimentation. Issues of 
‘biopolitics’, and more particularly the exercise of state power over the realm of life and 
biology, have been extensively discussed in studies of biotechnology in Asia and elsewhere in 
the world (cf. Rose 2007).  What remains less studied is the intricate entanglements of state, 
public and private actors, and the significance of such entanglements in the making of 
bioscience markets. Việt Nam offers a particularly interesting case through which to consider 
the networking ways through which biomedical economic formations come into existence.  
A latecomer into the game of competitive biotechnology compared to Asia’s so called 
‘biotech giants’ – such as China and Singapore - Việt Nam has been overlooked in relevant 
literature (Walberg 2009:241). Though stem cell science is still in its infancy, there is a flurry 
of pertinent entrepreneurial activity in this market socialist country. Such economic activity 
is generally facilitated by state-backed collaborative science projects implicating an array of 
institutional actors including national universities, public and private hospitals, health 
departments, scientific committees and biotech firms. The stated aim of such ‘national 
science projects’, as they are called in Viet Nam, is to develop stem cell products for the 
market and build viable biomedical businesses. Developing stem cell applications that can be 
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easily put into commercial uses is an official policy priority, and an entrepreneurial approach 
to bioscience research, is a disposition carefully cultivated in Vietnamese state-funded 
universities and public hospitals. This prioritization of commercial uses and applicability is 
further pursued in official policy by means of directing stem cell research away from highly 
innovative and often controversial practices – that many Vietnamese experts associate with 
China - and towards replicating technologies that have long been tested and approved in 
Euro-American contexts, with the view to making such technologies available to patients at 
much lower prices.  A case in point, is a recent ‘national science’ award made to a public 
university laboratory to fund a field trip to stem cell centres in Europe in order to identify 
methods that could be easily ‘transferred’ to Việt Nam, as a leading scientist at the laboratory 
put it.  
State involvement in economic life bespeaks as much of Việt Nam’s particularities as 
a market-oriented socialist country, as of general trends in the development of biotechnology 
industries.1 The ethnographic case presented here allows studying not only the crucial role of 
public private network partnerships in developing biomedical industries, but most 
importantly studying the ways in which scientific pursuits, business concerns and official 
practices become inexorably enmeshed in market-making processes. In what follows, I trace 
collaborative efforts to conduct research and turn bio-matters into for-profit ventures. 
The article is based on fieldwork conducted in 2014-15 in Việt Nam’s two main stem 
cell hubs, namely Hà Nội and Hồ Chí Minh City. Fieldwork allowed engaging with a range of 
actors involved in stem cell applications including university staff and students, laboratory 
researchers, medical practitioners, hospital administrators and biotech staff, as well as 
members of government-run committees regulating biomedical research. Circumstances in 
the field limited engagements with patients. In Việt Nam, patient organisations are scarce and 
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tightly controlled by the government and the prospect of my interacting with patients, let 
alone activists, was alarming to my informants. My declared scholarly interest on stem cell 
practises in Việt Nam was appreciated by informants, not least as holding promise for 
fostering links with academic communities abroad and bringing Vietnamese biomedical 
endeavours to international attention. Even so, efforts to gain research access to laboratories, 
hospitals and biotech firms were not without challenges. In several instances where 
informants granted research permission, they took the initiative of arranging group 
interviews by inviting their colleagues and associates to partake. This methodological 
imposition brought the collaborative engagements animating the formation of stem cell 
entrepreneurial networks into analytical focus. 
 
On bioscience markets 
The complex relationship between bioscience and economic processes has been a central 
concern in the social study of biotechnology (Rose 2001; Waldby 2002; Waldby & Mitchell 
2006; Rajan 2006; Cooper 2008a).  This relationship is often described by employing an array 
of ‘bio-concepts’ (Birch & Tyfield 2012:300), such as ‘bioeconomics’ (Rose 2001), ‘biovalue’ 
(Waldby 2002) and ‘biocapital’ (Rajan 2006). For instance, writing on the rapidly expanding 
economies of exchange in human tissue in Britain and the United States, Waldby and Mitchell 
(2006) look at the technical manipulation and circulation of bodily fragments and their 
increasing enmeshment with processes of ‘capitalisation’ and market value creation, and 
elaborate a theory of ‘biovalue’. ‘Biovalue’, a term introduced in earlier work by Waldby 
(2002:313), is defined as the (re)generative and productive capacities of living entities that 
can be ‘instrumentalised’ so as to become useful to human science and market projects.  
Further writings elaborate on theories of bioeconomy that conceptualise biological 
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substances as highly productive resources that can be manipulated to yield a ‘surplus’ of both 
life and economic value (Cooper 2008a; Rajan 2006). Such studies advance understandings of 
science development and its relation to political economy by reflecting on the production of 
new organics forms and life-enhancing technologies and the ways in which such forms might 
be invested with moral and economic values and enter gift or commodity circuits, and the 
ethical and social issues arising thereupon. However, reflections on life science matters and 
how these could become calculable commodities (or not) is predicated on an assumption of 
biological substances as highly productive resources endowed with inherent vital properties, 
on the basis of which social processes of valorisation and calculation proceed. Biological 
substances are thought as imbued with animating qualities that can be processed to produce 
both improved health and economic development. Therefore, paradoxically, the analyses of 
the social production of bioscience and markets is premised on a given, pre-existing 
‘biological’. Such epistemological premises, which have implications for the analysis of science 
and markets, have been criticised in an array of seminal anthropological and sociological 
writings that challenge taken-for-granted understandings of both ‘nature’ and ‘society’ 
(Viveiros De Castro 1998; Ingold 2000; Latour 2005). As Latour (2005) and other actor-
network-theory scholars suggest what is ‘nature’ and what is ‘society’ cannot be taken for 
granted but instead should be the very object of sociological enquiry. 
In reworking a theory of biovalue, a set of further studies shifts attention from 
biological specimens to their reformulation as information, suggesting that it is information 
on bio-matters and their therapeutic potential that fuels the capitalisation of human tissue 
and business investment on biotechnology (Novas 2006; Martin et al 2008; Petersen et al 
2011).  Considering the role of media representations, public and scientific discourses in 
raising patients’ expectations for medical breakthroughs, these studies point to hyped 
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‘regimes of hope’ as forming the basis of commodity value and the emergence of ‘promissory 
bioeconomies’ (Martin et al 2008: 127).  
Promissory discourses and speculative narratives on future economic value have 
become key conceptual elements in the social analysis of biotechnology markets. This 
scholarly emphasis on narratives and future potentialities is perhaps not surprising given the 
radical uncertainty manifest in the practice of bioscience. In the stem cell field, this 
uncertainty arises from largely experimental practices, difficult-to-prove results and the 
manifold risks to human health and entrepreneurial undertakings entailed therein. Presently, 
only a handful of stem cell applications have been clinically proven to be safe and effective in 
treating diseases, and even in this case it is widely acknowledged that long-term health effects 
remain unknown. And so, speculation is vital in the process of creating life science capitalist 
formations as Cooper (2008a) astutely observes. Yet, speculation is important for 
understanding bioscience markets if we are to study speculation as a practice – an effort to 
raise profit on the promise of surplus value - rather than as pertaining to abstract thought. 
Beyond exercises in speculation, the making of biomedical commodities and markets involves 
an array of scientific, official and entrepreneurial practices that remain understudied. 
Reflections on bioeconomy throw ample light on the economic imaginaries entailed 
in the development of life sciences and the rationalities underpinning bioscience capitalist 
formations. However, as Cooper and Waldby (2014) suggest this scholarly emphasis on vision 
and speculative discourses should not come at the expense of studying the work involved in 
the capitalisation of life sciences. Cooper and Waldby (2014) call attention to the 
unacknowledged ‘clinical labour’ performed by patients and donors by means of giving 
samples to biobanks and taking part in biomedical experiments, pointing out that this visceral 
and risky labour, which is often performed by socially marginalised and uninsured patients, is 
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critical for understanding biomedical modes of production. Producing stem cell products is 
indeed a painstaking and labour-intensive process implicating a diversity of actors and a series 
of transformative sequences: from knowledge instilled in science students in universities and 
advanced by researchers in laboratories to micro-parts extracted from humans bodies and 
subsequently isolated into identifiable parts that are induced to proliferated in test rooms 
before being transplanted into patients whose health condition is monitored in the context 
of clinical trials, the results of which are translated into scientific evidence submitted to 
scientific committees to be considered for approval as patented stem cell products for the 
healthcare marketplace. The ethnographic exploration into Vietnamese stem cell ventures 
presented here casts further light into aspects of this laborious process by considering the 
expert clinical practices, entrepreneurial undertakings and official procedures involved in 
setting up clinical experiments and translating results into commercial ventures. 
This ethnographic exploration into makings of stem cell enterprise draws on network-
based approaches to the study of technoscience that allow for practice-focused research and 
an appreciation of the complex social interactions through which markets come be 
constituted (Latour 1983; Callon 1986; Sleeboom-Faulkner 2011, 2014). Callon’s (2007) 
understanding of markets as ‘performative’ rather naturally occurring phenomena based on 
innate human tendencies serves as a particularly inspirational resource here. Callon (1986) 
suggests that new economic spaces and markets are created by means of configuring complex 
networks implicating a heterogeneity of actors, including human and non-human ones, such 
as microorganisms, theories, polices and devices, as well as the careful arrangement of 
relations between these actors. Engaging with such insights the article examines stem cell 
markets as socially constituted, paying particular attention to the collaborative engagements 
that allow configuring bio-matters into detachable and identifiable entities with ‘objectified’ 
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properties that can be turned into calculable objects to be transacted (Callon & Muniesa 
2005). The actors involved in Vietnamese biomedical entrepreneurial networks – be it human 
subjects, policy documents or bodily fragments - are not considered here as having fixed traits 
and pre-existing agendas. Rather the emphasis is placed on transfigurations and how actors 
are being continuously (trans)formed by means of taking active part in assembling biomedical 
networks. Two ethnographic instances discussed later here illustrate the point, namely that 
of a trainee doctor turned bioentrepreneur and a newly-founded biotech firm. Both emerge 
as entrepreneurial actors through their involvement in collaborative stem cell clinical 
research projects. 
This empirically grounded study of stem cell entrepreneurial networks in Việt Nam 
engages with calls for embedded understandings of markets that anthropologists and political 
economy thinkers have repeatedly articulated (Polanyi 1944; Granovetter 1985; Hefner 1998; 
Callon & Muniesa 2005; Smart & Smart 2005). Hefner’s edited volume Market Cultures 
(1998:2) as well as writings on Petty Capitalists (Smart and Smart 2005) reiterate the need for 
more sociologically realistic and empirical inquiries into economic life. Ethnographically 
grounded studies of capitalist markets do not merely add to the ethnographic record and 
comparative analysis by exploring the variable articulation of capitalist formations, but 
further allow obviating abstract understandings of economic life as well as the risk of 
repeating essentialising generalisations about science, nature and the social more generally. 
 
Stem cell networks 
Stem cell research and applications is a rapidly growing field in Việt Nam. In the past decade, 
stem cell science and its profit-making potential have attracted considerable interest, with an 
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array of public and private bodies joining in biomedical research projects geared towards 
developing commercial applications. Recent market reforms and sweeping changes in 
healthcare policy have created the conditions for scoping stem cell science as a ‘new 
profitable business in Việt Nam’ and assembling biomedical networks (VietnamNet 2013). 
The set of ‘renovation’ policies known as đổi mới introduced by the socialist state in 
1986 ushered in economic transformation signalling a move from a centrally planned to a 
market-oriented economy. Still ongoing, such reforms had a profound impact on the health 
sector changing how healthcare is delivered, managed and funded. Since 1989, a series of 
policies have sought to decentralise, deregulate and open up the health sector to market 
forces, by means of legalising private medical practice, privatising pharmaceutical production 
and sales, imposing charges in public hospitals, and introducing state-funded and voluntary 
health insurance schemes (Chen & Hiebert 1994; Ladinsky 2000; Tran et al 2011; Kerstin 
2012). The introduction of ‘user fees’ in public hospitals was a significant step towards 
creating for-profit opportunities in healthcare. In recent years, the Vietnamese state has 
transferred responsibility to public hospitals for raising and managing their own funds 
granting them greater ‘autonomy’ (Tran et al 2011). In this context, public hospitals are 
becoming increasingly oriented towards the provision of cutting-edge expensive biomedical 
technologies as a way to boost their income.  
Public hospitals are at the forefront of experimentation with both stem cells and 
biomedical entrepreneurial projects. Stem cell applications are mainly undertaken in 
hospitals run by the state or army.2 National haematology units are a case in point, making 
the most out of readily available blood resources, which can be used to harvest stem cells, to 
build commercial stem cell treatment and storage services. A telling case is the Haematology 
hospital in Hồ Chí Minh City, which pioneered the first stem cell transplant in the country 
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(1995) using bone marrow cells to treat a blood-cancer patient. Since then, it has ‘successfully 
carry out hundreds of transplants’, according to past and current directors (Tran Van Be et al 
2008:146). Today, the hospital is poised to launch a commercial stem cell bank alongside its 
national blood storage services, fostering ambitions to trade in stem cells with foreign 
partners in Europe and beyond.  
Since the first stem cell transplant in 1995, a series of public hospitals have seized 
upon stem cells as a potentially lucrative pursuit, especially in Hồ Chí Minh City. Since 2004, 
state and army-run hospitals in Hà Nội have been busy setting up stem cell units, building 
capacity and expertise by teaming up with basic researchers in public university laboratories 
and biotech companies to conduct research, and translate findings into scientifically proven 
‘therapies’ that could be subsequently considered by government-sponsored science 
committees for commercial license. 
Such collaborative research projects are conducted under the auspices of ministries 
as ‘national science projects’ (Đề tài nghiên cứu khoa học cấp nhà nước). Stem cell projects 
are mainly supported by the Ministry of Health that oversee all relevant undertakings, issuing 
permissions for basic and clinical research and running scientific and ethics committees that 
assess research proposals and findings.3 National stem cell projects are allocated some funds 
from government coffers, but such funding is ‘limited’ and ‘insufficient’ for covering the 
substantial costs involved, as Vietnamese scientists and policy makers remarked. To fill the 
funding gap in national projects, official policy actively encourages private interests to invest 
and work with state-run and public institutions in order to develop commercial applications. 
Science regulatory policy seeks to expand stem cell networks further and increase 
their chances in yielding commercially viable results. Like elsewhere in Asia, the Vietnamese 
government takes an economic - if not ‘permissive’ (Isasi & Knoppers 2006) - approach to 
 12 
 
CRITIQUE OF ANTHROPOLOGY 
regulation, governing bioscience though minimal rules and ‘soft law’ and a near-absence of 
policy implementation instruments.4 In this regulatory environment, state-sponsored science 
committees become an important node in stem cell enterprising networks contributing to 
stem cell product development through processing research licenses and commercial 
approvals (see later here). 
National projects seek to animate market forces in yet more ways. National schemes 
support research that is ‘applicable’ and has good commercial prospects, as a chief laboratory 
scientist commented. The commercial potential of stem cell applications is top in the agenda 
of health officials and a key criterion for approving research licenses and funding. To expedite 
the pathway to market and secure state support Vietnamese basic and clinical researchers 
employ stem cell techniques that have long been tested and applied, especially in ‘Western 
contexts’ (miền Tây). In the words of a chief scientist in a stem cell laboratory, ‘in Việt Nam 
we use simple techniques, like autologous transplants and hematopoietic stem cells that carry 
fewer complication risks’ (see also Van Be et al 2008:146). For similar reasons, mesenchymal 
stem cells, which are widely reported to have many potential applications, are becoming the 
mainstay of biomedical practice in Viet Nam. 
Despite claims by doctors and laboratory scientists, the effects and risks of stem cell 
applications in Việt Nam - much like elsewhere in the world - remain largely unknown. Regular 
reports in the state-controlled Vietnamese press entertain public perceptions about the cost 
and effects of stem cell applications, portraying clinical experiments as life-saving 
‘treatments’ offered to patients ‘free of charge’ in public hospitals. However, to date there 
are no stem cell ‘therapies’ officially approved to be safe and effective, and any future 
treatments will only be accessible to wealthy paying or privately insured customers, as 
indicated by doctors and biotech staff I conversed with. 
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Such admissions did not deter my interlocutors’ efforts to develop stem cell 
applications. At the time of my fieldwork, a number of research projects were underway, 
notably ‘clinical trials’ (thử nghiệm lâm sàng) conducted in hospitals in Hà Nội and Hồ Chí 
Minh City. These clinical studies provided the means not only for exploring the remedial 
benefits and safety of stem cell applications but further for launching an array of for-profit 
stem cell ventures, as demonstrated in the following two sections. 
 
Clinical trials and the making of bio-entrepreneurs 
A number of clinical studies recorded during fieldwork experimented with autologous stem 
cell transplants for the treatment of knee osteoarthritis and spinal cord injuries, conditions 
that affect many in Việt Nam (Fan 2012).  The focus of attention here is a ‘clinical trial’ (thử 
nghiệm lâm sàng) assessing the effects of adipose tissue extracted stem cells for the 
treatment of spinal injuries. The ‘trial’ was conducted in a major public hospital in Hà Nội - I 
will call it Thân.5 Founded by the French colonial administration the hospital is still one of the 
country’s major medical units. The study was a ‘national project’ conducted under the 
auspices of two government ministries and sponsored by a newly-founded biotech firm. The 
biotech and its collaborative engagements with the hospital are discussed in the next section. 
This section focusses on the professional activities of the medical team leading the spinal cord 
study, and a young doctor in particular. I will call this young doctor Doanh, as in doanh nhân 
that means ‘businessman’, a most fitting pseudonym as it transpires. The unfolding of Doanh’s 
educational and professional career trajectories allows for tracing the ways through which 
young doctors acquire stem cell expertise and come to engage in biomedical business. 
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I am a spinal surgeon. In Việt Nam we have many road and work-related accidents 
that result in spinal cord injuries, and my hospital has the largest influx of such 
patients in the country. There is a swelling demand for relevant medical services and 
great potential there… 
Some of the words with which Doanh introduced himself when we met in a hotel lobby. 
Dressed in a smart blue suit, akin to Vietnamese business folk, he chatted on his smartphone 
to his ‘big boss’, finalising details for my research visit to the hospital in order to meet the rest 
of the spinal cord study team. The ‘big boss’ was Doanh’s academic supervisor – or ‘mentor’ 
as Doanh referred to him - and the director of the hospital’s orthopaedics ward where the 
trial took place. Doanh was one of two doctors leading the study as ‘co-principal investigators’ 
(co-PI). At the time, Doanh was completing his graduate medical education, doing a PhD in a 
national medical university.  As part of his PhD, Doanh was doing in-service training at Thân 
hospital’s orthopaedics unit. Like most major public hospitals in Việt Nam, Thân is a university 
hospital, serving as a trusted surgical unit as well as a training facility for medical students. 
Born to a family of doctors - his father a medical university professor and his mother practising 
‘traditional medicine’ – Doanh was one of few students fortunate to gain access to this highly 
competitive residency training scheme. Acting as co-PI in the study was integral part of his 
residency training. Through Doanh was a co- PI in the ‘trial’ he was not authorised to carry 
out stem cells interventions on participating patients. A more senior doctor with several years 
of medical professional ‘experience’ and service at the very hospital performed all stem cell 
procedures, while the director of the orthopaedics ward oversaw and authorised all 
procedures. Nonetheless, the study allowed Doanh to build expertise in using stem cells on 
patients with orthopaedic conditions. 
The three-year spinal cord study was officially the first stem cell project at Thân hospital. 
It was conducted in a sparkling new tower-building where the orthopaedics ward had recently 
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relocated. By way of initiating me to the ‘trial’, Doanh gave me a tour around the orthopaedics 
ward pointing to participating patients and explaining their condition and stem cell treatment. 
First there was a girl in her twenties with a ‘very serious condition affecting her movement 
and bodily functions’, Doanh explained. Pointing to her abdomen, Doanh explained that a 
tissue sample had just been extracted and was on its way to the laboratory to isolate and 
process stem cells in order to inject back to the young patient as part of the trial.  Next, Doanh 
pointed to a young man suffering partial paralysis after falling from a height in a construction 
site, and then a middle-aged family man affected by a similar condition. Stressing the 
graveness of patients’ conditions, Doanh cautiously pointed to ‘improvements’ since the start 
of the ‘trial’. Such improvements were, however, only slight relating mostly to patients’ 
‘quality of life’, such as the ability to control urination, as Dr Triệu, the other co-PI at the trial 
and senior doctor who carried out stem cell interventions on patients, explained. Dressed in 
a white coat, Dr Triệu took the lead in answering my questions about the ‘trial’ in a group 
interview that Doanh had organised and included staff from the biotech firm sponsoring the 
‘trial’ (see next section). Voicing a cautious approach to promissory narratives, Dr Triệu 
pointed out that despite best efforts by the medical and biotech team to extract, proliferate 
and carefully plan and administer stem cell transplants, there were no significant 
improvements in the patients’ condition in the course of this study. In his words: 
The trial has been running for three years and concludes in a few months but it has 
not produced any positive results. We used stem cells to treat acute spinal cord injury 
but we cannot claim significant improvements in the patients’ condition... 
Participating patients were selected on the basis of their level of injury; they are 
people with acute spinal cord trauma who do not have complete paralysis. They also 
have little to lose. The patients had stem cells transplants applied six months after 
surgery. Their chances in recovery are very low. They might get better, but it is not 
likely that this will be due to stem cells. 
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This ‘trial’ may have failed to produce positive remedial results, but turned out to be 
productive in other regards, allowing a number of actors involved to launch further research 
and entrepreneurial projects. Firstly, inconclusive clinical results provided the basis for the 
hospital applying and securing further ministerial support for a new national ‘clinical trial’ on 
spinal cord injury. The study would be led by the same two doctors, thus allowing them to 
build pertinent expertise. The new trial - which was regarded by medical and biotech staff 
involved as a ‘continuation’ of the first - would also enable the hospital to build stem cell 
capacity with the view to offering pertinent services to paying customers in the near future. 
The same biotech firm would sponsor the second ‘spinal cord trial’ as well as further stem cell 
studies due to start at the hospital the year after. Sponsoring projects in a major public 
hospital effectively allowed the biotech to build a stem cell business, as explained in the next 
section. Finally, Doanh emerged out of this inconclusive clinical study as a stem cell specialist 
and a budding bioentrepreneur. In subsequent interviews, Doanh spoke about plans to 
formally launch a private company offering a range of medical services, including stem-cell 
related ones, as soon as the ongoing trial and thus effectively his PhD training concluded. 
At the time of my fieldwork, Doanh and his business partner - a man in his late 
twenties with a Master’s in economics and experience in selling medical supplies - were in the 
process of launching a private medical services company, and stem cells were at the core of 
their business model. The company had three divisions: a web-based information network on 
stem cell treatments and practitioners available in Việt Nam; a private clinic specialising in 
orthopaedics treatments including stem cell-based ones, and a stem-cell-related product 
distribution network. 
The website was already running at the time of my fieldwork. It provided information 
on stem cell treatments and specialists in Việt Nam to patients wishing to ‘buy treatments 
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and healthcare services’ through a log-in system, Doanh’s partner explained. This log-in 
service collects data on patients’, hence creating a database that can be then sold to clinics 
and medical professionals, he added. In a group interview with the two business partners, 
Doanh excitedly revealed that he had just secured official licence to open the private clinic. 
Doanh explained that the clinic would have twenty members of staff including four doctors 
and a dedicated stem cell unit. Doanh was also looking to capitalise on the stem cell expertise 
gained through his residency training by providing consultancy on stem cell trials and 
treatments to other hospitals. In his words: 
After I finish my PhD I want to advise hospitals on how to conduct stem 
cell clinical trials and build dedicated units. I am currently involved in more 
than one national projects on stem cells and there are many hospitals, 
both private and public, looking to provide stem cell services.  
Apart from the private clinic and website, the two partners were also setting up a distribution 
network providing stem-cell-related products, like ‘extraction kits’ and machinery for 
processing tissue, to hospitals and clinics around Hà Nội. Through all these means, the two 
partners sought to make the most of a growing demand for stem cell services in Việt Nam, 
driven mainly by wealthy Vietnamese and health tourists from abroad. As Doanh put it:   
Rich Vietnamese currently travel to South Korea and Japan for stem cell 
procedures, both therapeutic and health-enhancing treatments. We want to keep 
them here. We also want to attract health tourists, especially Việt Kiều (overseas 
Vietnamese) from the USA, who could come to Việt Nam for stem cell treatments 
that are good but much cheaper than the US or Europe. We want their dollars. 
The young medical practitioner, Doanh, was not the only one to emerge out of involvement 
in ‘clinical trials’ as a budding bio-entrepreneur. A ‘biotech company’ (công ty công nghệ sinh 
học) came to build their stem cell trade through participation in the spinal cord study and 
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other national stem cell research projects conducted in a major public hospital, as illustrated 
in the next section. I will call this biotech Nhìn Xa, which translates as ‘visionaries’.  
 
Stem cell ventures 
Nhìn Xa biotech was formally launched a few months before the first stem cell ‘trial’ at Thân 
hospital started. The company was founded with this very purpose as stated on their website: 
to isolate, culture and supply stem cells to Thân hospital. The company’s formal opening (lễ 
khai trương) was marked by the ceremonious signing of a ‘cooperation agreement’ with the 
hospital. It was at this very hospital I first came to know about the biotech as a ‘sponsor’ to 
the spinal cord ‘clinical trial’ and met some of the company’s staff. The biotech staff tasked 
with liaising with Thân hospital over the spinal cord and other stem cell studies were four 
women and men in their mid- to late twenties who had flocked to the capital from other 
provinces to forge a career in science-based business upon finishing a Master’s degree in 
biotechnology. 
The spinal cord study is not the only stem cell project over which Nhìn Xa biotech and 
Thân hospital collaborated. The company sponsored two further ‘clinical trials’ at the 
orthopaedics ward due to start soon after the ongoing spinal cord trial concluded. One of 
these new trials was a continuation of the ongoing spinal cord study, while the other was on 
‘degenerative joint disease’. Further trials relating to various diseases were also to start 
around the same time in different wards at the hospital, notably a project on ‘liver disease’. 
All three aforementioned ‘trials’ were ‘national projects’ supported by ministries. Apart from 
‘clinical ‘trials’, the biotech is working with the hospital in carrying out small scale stem cell 
experiments concerning ‘rare degenerative conditions for which very little is known’, as Xuȃn, 
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one of the female biotech staff noted. These ‘are not clinical trials as they involve only one or 
two patients’, Xuȃn explained. Moreover, Xuȃn added, in these cases ‘patients pay for their 
treatment’ unlike clinical trials that are ‘free of charge’ for patients and the ‘sponsor covers 
all relevant expenses’. These informal try-outs initiated at the ‘patients’ request’, as well as 
formal ‘trials’, are often noted in the biotech’s brochures as ‘treatments’. Such promotional 
acts may or may not be indicative of future-bound attitudes to biomedicine but what is certain 
is that they affect in significant ways current stem cell practices in Viet Nam by blurring the 
boundaries between experiments and therapies.6 
According to their website, Nhìn Xa is the ‘first company [in Việt Nam] licensed by the 
Ministry of Health to culture and supply stem cells derived from adipose fat tissue’. Cuong the 
biotech’s young male R&D manager explained, ‘we can extract many different kinds of stem 
cells from adipose tissue, but we are interested in isolating and storing mesenchymal stem 
cells, as these have a diversity of possible applications for the treatment of a host of diseases’. 
Giving me tour around the biotech’s laboratory and storage facilities, Cuong explained about 
the biotech’s work and contribution to stem cell studies at Than hospital:   
 We obtain tissue that is extracted from patients treated at the hospital as part of 
clinical studies. After we extract the stem cells from the tissue we induce them to 
proliferate and we divide them so as to prepare a number of injections needed for the 
treatment of patients. Between injections we need to store stem cells, so, we also 
operate a stem cell bank. After the treatment [as part of the trial] concludes, we store 
the remaining stem cells for one year free of charge. Then, if the patients wish to 
continue storing them they pay an annual fee. Patients might need to use stem cells 
again for future applications. Healthy patients can also make [stem cells] injections 
to improve their general health. [Apart from the spinal cord study], we are looking to 
develop stem cell applications for a series of diseases as well as for cosmetic 
purposes.7 
Involvement in national projects in a public hospital is of crucial importance for the biotech’s 
fledgling business, allowing them to transform experiments with human bio-matters into a 
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range of commercial services. By means of sponsoring clinical studies, the biotech gains 
access to human tissue that is subsequently modified to form their main commodity, namely 
stem cells. This allows the biotech to kick start a stem cell storage service, by enlisting trial 
patients with the view to turning them to customers willing to pay for storing their samples 
for future applications after the conclusion of the trial. 
Another way through which the biotech seeks to build a stem cell business is by enlisting 
institutional clients and selling their expertise gained through the trial, as well as the 
intellectual property rights on the resulting technology to other organisations. Hospitals 
constitute one category of possible clientele, insurance companies another.  In the words of 
Xuân,  
After the spinal cord study concludes and is approved by the ministry [of Health] as a 
therapy the company will transfer the patented technology to other hospitals e.g. we 
will show them the specific methodology and train their doctors on how to apply it.  
The issue of who owned clinical results and methodologies was rather unclear with often 
conflicting views voiced during conversations and interviews depending on the interlocutor’s 
job and affiliate institution, thus pointing to many stakeholders. Biotech staff were cautious 
about making claims, saying that clinical results from the spinal cord study ‘belong to Than 
hospital’. But by acting as ‘sponsors’ to clinical studies and as evident from their business 
plans, the biotech staked a claim on resulting stem cell technologies. ‘Collaborating with 
insurance companies’ was another way the biotech sought to create a space for profitable 
transactions. Loan, one of the female employees, explained:  
At the moment, national insurance does not cover stem cell procedures, and neither 
do insurance companies. If the spinal cord treatment is approved by the Ministry of 
Health then insurance companies will be able to add it in their list [of therapies 
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covered], and hence gain a competitive advantage over other insurance companies. 
This is an opportunity for us to work with insurance companies and invite investment. 
Realising the economic potential of stem cell applications and turning profits out of uncertain 
investments hinges on transforming ‘clinical trials’ into scientifically tested and officially 
approved ‘therapies’ that can become commercially available. Government bodies and state 
agencies play a crucial role in this process of translation.  
 
From trial to therapy  
Health policy instruments, ministry-led science schemes and public bodies are important 
nodes in stem cell networks allowing research to take place and entrepreneurial undertakings 
to materialise. To begin with, most basic and clinical studies recorded during fieldwork were 
national projects conducted under the aegis of government ministries. Such projects allow 
assembling stem cell networks that bring together a number of disparate actors such as 
scientists working in national universities and laboratories, practitioners in public and private 
hospitals, local health officials, biotech staff and patients as well as biomaterial, scientific 
data, hi-tech equipment and facilities. Public bodies’ involvement and ministerial support 
allows not only gathering a diversity of human and non-human actors as well as the resources 
required for biomedical research but further facilitates the process of obtaining required 
research permissions and commercial biomedical licenses. Such licensing procedures allow to 
effectively transform biomedical research and clinical data into certified stem cell products 
for the healthcare market. 
Licensing and quality controls in biomedicine, and healthcare in general, are reported to 
be poor and undeveloped in Việt Nam (Tran et al 2011). However, several licensing 
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applications for certifying stem cell technologies as safe and effective for the healthcare 
market were in progress during my fieldwork, and some of them secured approval. Official 
licensing procedures support the development of stem cell commodities in every step of this 
long process, not least by means of enabling a series of transformations. To start with, a 
license is required to engage in basic research with such licenses granted only to studies taking 
place or involving the participation of public universities. Basic research results form the basis 
for securing a license for the next main stage in stem cell research which is clinical 
experiments with animals.  The results of ‘animal model’ research can be used to apply for 
official permission to conduct ‘clinical trials’ involving patients. The involvement of public 
hospitals is again crucial here. The case of a private clinic that partnered up with an army-run 
hospital with no stem cell expertise and appropriate amenities by way of acquiring approval 
to conduct ‘trials’ illustrates the point. Crucially, official approvals are essential for translating 
often tentative stem cell clinical experiments with patients into officially certified 
commodities that can be transacted. Talking about the spinal cord study Loan at the biotech 
explained: 
The state [nhà nước] has to decide if the therapy is safe and efficient. The ministry of 
health is vetting the whole process, running checks on participating scientists and 
doctors and making sure we follow correct procedures and abide with laws and 
regulations. After we complete the trial, we report the results to the ministry (báo 
cáo nghiên cứu). We have to wait for the ministry to assess trial results, which can 
take up to two or three years of meetings upon meeting, which is a long time for 
patients to wait.  
There is a lengthy, multi-step process involved in responsibly translating science and research 
into safe and effective treatments (Salter 2008). By way of explaining the process in Việt Nam 
my interlocutors at Nhìn Xa biotech counted the main steps involved. After the ‘trial’ 
concludes, the hospital and biotech team that led the project report to the hospital’s 
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orthopaedics ward management, which in turn considers results and subsequently reports 
higher up the rank to the hospital’s ‘science council’.  The council will then formally report trial 
results to the Health Ministry’s ‘Bureau of Administration for clinical trials’ (Cục quản lý thử 
nghiệm lâm sàng, Bộ Y Tế). ‘This bureau will decide whether this method is good for the 
patients or not, whether it is safe (an toàn) and effective (hiệu quả)’, as Xuân at the biotech 
put it. 
To increase their chances in procuring official permissions and approvals that would 
allow turning trial results into marketable commodities the two partners, Thân hospital and 
Nhìn Xa biotech, collaborated with a number of state-run institutions. Specifically, the spinal 
cord study involved cooperation with two other public hospitals for the purposes of ‘aiding 
patients’ recovery’ and ‘verifying clinical results’, Xuân explained.  A ‘national’ hospital 
provided trial patients physiotherapy sessions, especially those who had problems controlling 
urination, and monitored overall progress in their condition through ‘somatosensory’ muscle-
related and MRI tests.  An army-run hospital also run regular checks on clinical trial data to 
identify possible improvements in the patients’ condition. 
In market socialist Việt Nam, state involvement in stem cell ventures is regarded with 
ambivalence by scientists, doctors and experts in public and private institutions partaking in 
national projects. Many protest that protracted ‘bureaucratic procedures’ and burdensome 
‘ethical requirements’ often encumber biomedical projects by adding to workload and delays. 
Yet, government schemes and public body participation allow stem cell projects and 
potentially profitable outcomes to materialise, thus playing a vital role in turning the promise 
of stem cell science, and often unpromising research results, into vetted ‘therapies’. Through 
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Conclusion 
The global rise of bio-industries has in recent years captured the attention of anthropologists 
and science studies scholars often serving as a vehicle for analysing contemporary capitalism 
and its changing trajectories. Bioscience is thought by many scholars as well as policy makers 
as a perfect example of a ‘new economy’ that could be a major driver for social and economic 
development.  Life sciences, with its potential to create new organic forms that can prove to 
be productive and beneficial in number of ways, has become a field for sprawling speculative 
activity and investment. In Việt Nam, efforts to encourage economic activity in the field of 
stem cells and build a biomedical industry are ongoing and intensifying. 
Despite burgeoning entrepreneurial activity in the field of stem cells in Việt Nam and 
elsewhere in the world, stem cell undertakings are beset by a number of fundamental 
uncertainties. Stem cell science and applications are still largely experimental and potential 
benefits regarding human health, often advocated by scientists and policy makers, are yet to 
be substantiated.8 On that basis, it is difficult to consider stem cells and related bio-matters 
as given and naturally productive sources of vitality and wellbeing that can produce health 
and financial gains. Rather how body micro-parts come to be engineered into identifiable 
organic forms with potentially life-giving properties, on the basis of which they are 
constituted as valuable commodities to be transacted should be very object of social 
enquiries. The ethnographic case presented here illustrates that in market socialist Viet Nam, 
state-backed clinical research serves as a primary means for developing commercial 
applications and ventures in biomedicine. Such experimental processes do not merely assess 
the therapeutic potential of stem cell applications on patients but also engineer biomedical 
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technologies and entrepreneurial actors. Government-supported experiments and licensing 
procedures allow developing marketable stem cell applications despite inconclusive clinical 
data and uncertain results. Looking into how clinical experiments are organised and 
conducted in Việt Nam allowed tracing the entanglements of stem cell science, 
entrepreneurial undertakings and official practice, and the significance of these 
entanglements for understanding emerging biomedical industries. Through these means, this 
ethnographic exploration into the makings of Vietnamese stem entrepreneurial networks 
hopes to add to empirical inquiries on the social constitution of markets.  
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1 Ong and Chen’s (2010) volume point to a general trend towards ‘state entrepreneurialism’ in creating 
effervescent bioscience economic activity. Rajan (2006) also notes that state policy and funding have played a 
key role in the development of bio-industries in the United States.  
2 Some of the hospitals involved in stem cell applications are the Paediatric Institute, Bach Mai Hospital, Blood 
transfusion and Haematology Institute, 103 and 108 Military Hospitals in Hà Nội, and the Blood Transfusion and 
Haematology Hospital and 115 People’s Hospital in Ho Chi Minh City.  
3 The Ministry of Science and Technology also sponsors stem cell studies.  
4 The first regulations on clinical research were introduced between 1996 and 2002. In 2007, the Health Ministry 
laid out a plan to introduce further regulations and guidelines for good practice. However, by official admission, 
the regulatory framework remains ‘weak’ (see MoH Report 2009). 
5 As in thân hình (body). All names used in this article are pseudonyms.  
6 We also need to allow for culturally specific medical understandings and practices, which however fall 
beyond the scope of the article.  
7 To date using stem cells for cosmetic purposes is banned in Viet Nam, but several private clinics advertise 
such services.  
8 This uncertainty about the safety and efficiency of stem cell applications applies unevenly in different 
sociotechnical settings around the world, nevertheless it persists as a general condition. 
 
 
                                                     
